Skip to main content
DELCATH SYSTEMS, INC. logo

DELCATH SYSTEMS, INC. — Investor Relations & Filings

Ticker · DCTH ISIN · US24661P8077 LEI · 549300NVPLITUM6URT02 US Manufacturing
Filings indexed 1,105 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US DCTH

About DELCATH SYSTEMS, INC.

https://delcath.com/

Delcath Systems, Inc. is a commercial-stage interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes proprietary products for percutaneous hepatic perfusion (PHP), a minimally-invasive procedure designed to administer high-dose chemotherapy directly to the liver while controlling systemic exposure. Its flagship product in the United States is the HEPZATO KIT™ (melphalan/hepatic delivery system), an FDA-approved drug/device combination product for treating adult patients with metastatic uveal melanoma. In Europe, the company markets the CHEMOSAT® Hepatic Delivery System, a medical device for the same procedure.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-14 English
10-Q - DELCATH SYSTEMS, INC. (0000872912) (Filer)
Interim / Quarterly Report
2026-05-07 English
8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)
Regulatory Filings
2026-05-07 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-04-27 English
ARS - DELCATH SYSTEMS, INC. (0000872912) (Filer)
Annual Report
2026-04-02 English
DEFA14A
Proxy Solicitation & Information Statement
2026-04-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.